IMBRUVICA Drug Patent Profile

When do Imbruvica patents expire, and when can generic versions of Imbruvica launch?

Imbruvica is a drug marketed by Pharmacyclics Llc and is included in three NDAs. There are fifty-seven patents protecting this drug and four Paragraph IV challenges.

The generic ingredient in IMBRUVICA is ibrutinib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ibrutinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Imbruvica

Imbruvica was eligible for patent challenges on November 13, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 30, 2034. This may change due to patent challenges or generic licensing.

There have been twenty-one patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are six tentative approvals for the generic drug (ibrutinib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for IMBRUVICA

US Patents:	57
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	76
Clinical Trials:	151
Patent Applications:	5,809
Drug Prices:	Drug price information for IMBRUVICA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for IMBRUVICA
What excipients (inactive ingredients) are in IMBRUVICA?	IMBRUVICA excipients list
DailyMed Link:	IMBRUVICA at DailyMed

See drug prices for IMBRUVICA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IMBRUVICA

NDA:

205552

Dosage:

CAPSULE;ORAL

NDA:

217003

Dosage:

SUSPENSION;ORAL

NDA:

210563

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IMBRUVICA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Peter MacCallum Cancer Centre, Australia	Phase 2
Oncternal Therapeutics, Inc	Phase 3
Academic and Community Cancer Research United	Phase 2

See all IMBRUVICA clinical trials

Pharmacology for IMBRUVICA

Drug Class	Kinase Inhibitor
Mechanism of Action	Protein Kinase Inhibitors

Paragraph IV (Patent) Challenges for IMBRUVICA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IMBRUVICA	Capsules	ibrutinib	70 mg	205552	1	2018-12-14
IMBRUVICA	Tablets	ibrutinib	280 mg and 420 mg	210563	1	2018-12-14
IMBRUVICA	Tablets	ibrutinib	560 mg	210563	1	2018-11-05
IMBRUVICA	Capsules	ibrutinib	140 mg	205552	8	2017-11-13

US Patents and Regulatory Information for IMBRUVICA

IMBRUVICA is protected by eighty-eight US patents and five FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-001	Nov 13, 2013		RX	Yes	Yes					Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-004	Feb 16, 2018		DISCN	Yes	No					Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-003	Feb 16, 2018		RX	Yes	Yes					Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	SUSPENSION;ORAL	217003-001	Aug 24, 2022		RX	Yes	Yes
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-003	Feb 16, 2018		RX	Yes	Yes					Y

EU/EMA Drug Approvals for IMBRUVICA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International NV	Imbruvica	ibrutinib	EMEA/H/C/003791IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.	Authorised	no	no	no	2014-10-21

International Patents for IMBRUVICA

When does loss-of-exclusivity occur for IMBRUVICA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Finland

Guatemala

Hong Kong

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

Russian Federation

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IMBRUVICA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2011261185
Australia	2015275321
Australia	2018204179
Australia	2020202752
Australia	2022201741

Supplementary Protection Certificates for IMBRUVICA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2201840	C300728	Netherlands		PRODUCT NAME: IBRUTINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/14/945 20141021
2201840	CA 2015 00021	Denmark		PRODUCT NAME: IBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 20141021
2201840	PA2015017	Lithuania		PRODUCT NAME: IBRUTINIBUM; REGISTRATION NO/DATE: EU/1/14/945 20141021
2201840	C20150014 00145	Estonia		PRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 23.10.2014
2201840	15C0029	France		PRODUCT NAME: IBRUTINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/945 20141023

IMBRUVICA Market Dynamics, Financial Trajectory, Patent Exclusivity, and Competitive Outlook

Last updated: September 17, 2026

IMBRUVICA, the ibrutinib-based BTK inhibitor marketed by AbbVie and Johnson & Johnson, remains a major hematology product despite declining sales. Its commercial peak reflected broad use across chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, Waldenström macroglobulinemia, and marginal zone lymphoma. Revenue pressure now comes from second-generation BTK inhibitors, indication withdrawals, treatment sequencing changes, and future generic exposure.

AbbVie’s reported IMBRUVICA revenue declined from approximately $4.9 billion in 2022 to about $4.4 billion in 2023. Johnson & Johnson reported approximately $1.1 billion in 2023 sales outside AbbVie’s principal commercial territory. Combined global sales were therefore approximately $5.5 billion in 2023, down from roughly $6.1 billion in 2022 based on company disclosures. [1,2]

What is IMBRUVICA and which company owns it?

IMBRUVICA is the brand name for ibrutinib, an orally administered covalent Bruton’s tyrosine kinase inhibitor. It binds irreversibly to BTK and suppresses B-cell receptor signaling.

Item	Detail
Active ingredient	Ibrutinib
Brand	IMBRUVICA
Original developer	Pharmacyclics
Current commercial partners	AbbVie and Johnson & Johnson
Primary indication areas	CLL, SLL, WM, selected B-cell malignancies
Drug class	Covalent BTK inhibitor
FDA first approval	November 2013
Dosage forms	Capsules and tablets
Regulatory type	New molecular entity under the 505(b)(1) pathway
Biosimilar exposure	None; ibrutinib is a small molecule
Main competitive threats	Calquence, Brukinsa, Jaypirca, Venclexta-based regimens

AbbVie acquired Pharmacyclics in 2015 for approximately $21 billion. The acquisition gave AbbVie control of Pharmacyclics’ ibrutinib rights and substantially increased its exposure to hematology revenue. Johnson & Johnson retained commercialization rights through the earlier Pharmacyclics-Janssen collaboration. [3]

How has IMBRUVICA revenue changed over time?

IMBRUVICA moved from rapid launch growth to maturity and decline. The product’s commercial expansion was driven by label additions, movement into earlier lines of therapy, and high-duration treatment in CLL and SLL.

Year	AbbVie reported sales	Johnson & Johnson reported sales	Approximate combined sales
2019	About $4.0 billion	About $1.3 billion	About $5.3 billion
2020	About $4.1 billion	About $1.3 billion	About $5.4 billion
2021	About $4.5 billion	About $1.4 billion	About $5.9 billion
2022	About $4.9 billion	About $1.3 billion	About $6.2 billion
2023	About $4.4 billion	About $1.1 billion	About $5.5 billion

Figures are rounded from AbbVie and Johnson & Johnson annual reports and reflect different geographic reporting conventions. [1,2]

Why did IMBRUVICA sales peak?

The product benefited from several commercial factors:

1. Early approval in high-value B-cell malignancies.
2. Long treatment duration in CLL and SLL.
3. Broad physician familiarity with the first major BTK inhibitor.
4. Limited competition during the initial growth period.
5. Expansion into both treatment-naive and relapsed or refractory populations.

Revenue growth slowed as the market shifted toward time-limited regimens, combination therapy, and second-generation BTK inhibitors with more favorable cardiac safety profiles.

Why are IMBRUVICA sales declining?

The leading factors are competitive substitution and loss of clinical positioning.

Calquence, marketed by AstraZeneca, and Brukinsa, marketed by BeiGene, increasingly compete for CLL and other B-cell malignancies. Both products are positioned as more selective BTK inhibitors, with clinical and commercial messaging focused on lower rates of atrial fibrillation and other cardiovascular toxicities compared with first-generation ibrutinib.

Venclexta-based fixed-duration regimens also reduce the need for indefinite BTK treatment in some patients. Jaypirca, Eli Lilly’s pirtobrutinib, targets patients whose disease has progressed after covalent BTK inhibitor therapy and can capture later-line patients previously associated with IMBRUVICA.

What is the FDA regulatory status of IMBRUVICA?

IMBRUVICA retains FDA-approved uses in several hematologic malignancies, but its indication profile is narrower than during its peak.

The FDA approved ibrutinib in 2013 for mantle cell lymphoma after at least one prior therapy. The FDA later granted approvals in CLL, SLL, Waldenström macroglobulinemia, and marginal zone lymphoma. [4]

In 2023, AbbVie and Janssen voluntarily withdrew the U.S. mantle cell lymphoma indication after a required confirmatory study failed to establish the expected benefit-risk profile in the relevant treatment setting. The companies also withdrew the marginal zone lymphoma indication in the United States. [5]

The remaining commercial base is concentrated in:

• CLL
• SLL
• Waldenström macroglobulinemia
• Certain chronic graft-versus-host disease uses in adults and pediatric patients aged one year and older after failure of one or more systemic therapies

CLL and SLL remain the principal revenue drivers. The label changes reduce addressable volume and weaken the product’s ability to offset competitor share losses through new indications.

What patents protect IMBRUVICA?

IMBRUVICA’s patent estate includes composition-of-matter, crystalline form, formulation, and method-of-use protection. The U.S. Orange Book has listed multiple patents associated with ibrutinib products, including U.S. Patent No. 8,008,309 and later patents covering drug forms and uses. [6]

Patent category	Commercial purpose	Risk profile
Composition of matter	Protects ibrutinib chemical entity	Strongest historical protection
Solid-state or crystalline form	Protects specific active pharmaceutical ingredient form	Can delay generic launch if valid and infringed
Formulation	Protects tablet or capsule composition and delivery	Usually narrower than composition protection
Method of use	Protects treatment of specific malignancies or patient populations	Vulnerable to label carve-outs and use-based litigation
Manufacturing process	Protects selected preparation routes or intermediates	Can create technical barriers but may not block all generic manufacture

Core compound protection is generally associated with expiration in the second half of the 2020s, while later patents may extend protection for selected formulations, forms, or uses into the early 2030s. Patent-term adjustment, pediatric exclusivity, terminal disclaimers, and the specific Orange Book listing determine the practical launch date for each generic applicant.

When does IMBRUVICA lose exclusivity?

The commercial exclusivity analysis has several dates rather than one universal expiration date.

Exclusivity category	Expected significance
FDA orphan exclusivity	Relevant only to the indication and approval period covered by the orphan designation
New chemical entity exclusivity	Expired after the initial approval period
Core patent protection	Primarily late 2020s
Later formulation and use patents	May extend selected protection into the early 2030s
Pediatric exclusivity	Can add six months to qualifying patent or regulatory exclusivity periods
Generic entry	Depends on ANDA approvals, Paragraph IV litigation, settlements, and patent outcomes

The first meaningful U.S. generic-entry risk is likely to focus on the surviving core and formulation claims rather than on biosimilar competition. Any launch before the final listed-patent date would require a successful Paragraph IV challenge, a settlement allowing an earlier launch, or a court finding that the asserted patents are invalid, unenforceable, or not infringed.

What is the Orange Book status of IMBRUVICA?

IMBRUVICA is an Orange Book-listed small-molecule drug. The Orange Book identifies patents that the NDA holder represents as covering the drug substance, drug product, or approved method of use. Generic applicants must address relevant listed patents through Paragraph I, II, III, or IV certifications.

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. If the NDA holder files a patent-infringement action within the statutory period, FDA approval of the ANDA may be stayed for up to 30 months, subject to court and regulatory developments. [7]

The commercial importance of Orange Book patents is highest for:

• ibrutinib active-ingredient protection;
• tablet and capsule formulations;
• dosage regimens;
• treatment methods that remain on the FDA label;
• patents that can support a 30-month stay after a Paragraph IV filing.

Method-of-use patents can be less effective than compound patents because generic applicants may use a “skinny label” that omits a patented indication. That approach does not eliminate all infringement risk, particularly where the remaining label and prescribing practices materially overlap with a patented use.

Which companies are challenging IMBRUVICA?

The primary competitive challengers are not biosimilar manufacturers. They are branded hematology companies with alternative BTK or B-cell treatment products.

Competitor	Company	Mechanism or class	Commercial position
Calquence	AstraZeneca	Second-generation covalent BTK inhibitor	Direct CLL competitor with safety differentiation
Brukinsa	BeiGene	Second-generation covalent BTK inhibitor	Rapid share gains in CLL and other B-cell malignancies
Jaypirca	Eli Lilly	Noncovalent BTK inhibitor	Later-line treatment after covalent BTK exposure
Venclexta	AbbVie and Roche	BCL-2 inhibitor	Competes through fixed-duration and combination regimens
Rituxan and biosimilars	Roche and multiple manufacturers	Anti-CD20 antibody	Used in combination and alternative treatment regimens

Brukinsa and Calquence present the largest direct substitution risk in earlier-line BTK treatment. Jaypirca is more complementary and captures patients who progress after IMBRUVICA, Calquence, or Brukinsa.

How strong is the IMBRUVICA patent estate?

The estate is commercially strong in the near term but weaker than it was during the product’s growth phase.

Its strengths include:

• a historically important composition-of-matter position;
• multiple dosage-form and formulation patents;
• a large installed patient base;
• substantial clinical data supporting continued use;
• switching friction in patients who are stable on therapy;
• regulatory and manufacturing experience concentrated among a small number of potential entrants.

Its weaknesses include:

• increasing competition from newer BTK inhibitors;
• narrowing U.S. indications;
• likely generic attention as core patents approach expiration;
• potential label carve-outs for method-of-use claims;
• declining treatment duration as fixed-duration regimens expand;
• cardiovascular safety concerns associated with first-generation BTK inhibition.

Patent protection can delay generic erosion, but it cannot fully protect market share from branded therapeutic substitution. IMBRUVICA’s most immediate commercial threat is therefore product-level competition, not generic entry.

What patent litigation and Paragraph IV risks affect IMBRUVICA?

The principal litigation risk is expected to arise when ANDA applicants challenge Orange Book-listed patents covering ibrutinib and its approved formulations. The timing and impact depend on several factors:

1. The number of ANDA filers.
2. Whether the first filer receives 180-day generic exclusivity.
3. The patents selected for Paragraph IV challenges.
4. Whether AbbVie or Janssen brings infringement actions.
5. Whether courts uphold the asserted claims.
6. Whether the parties settle and establish an authorized or licensed launch date.

An authorized generic could materially change the erosion curve. AbbVie or Janssen could use an authorized generic, licensing agreement, or settlement to capture part of the post-entry market while controlling the timing of broader generic competition.

No biosimilar litigation framework applies because ibrutinib is a chemically synthesized small molecule rather than a biologic. Generic applicants will proceed through ANDAs, not abbreviated biologics license applications.

What generic launch scenarios exist for IMBRUVICA?

Scenario 1: Delayed entry after core patent expiry

A court upholds key patents or no early settlement occurs. Generic launch begins after the last enforceable core patent or listed formulation patent expires. Price erosion is gradual at first but accelerates as multiple manufacturers enter.

Scenario 2: Settlement-based early launch

AbbVie, Janssen, and generic applicants agree to a licensed entry date before all listed patents expire. The settlement may include an authorized generic or restrictions on launch timing and dosage forms.

Scenario 3: Successful Paragraph IV challenge

A court invalidates or finds noninfringement of the patents asserted against a first filer. Entry can occur substantially earlier than the nominal expiration date and may produce rapid price compression.

Scenario 4: Limited skinny-label entry

Generic manufacturers omit patented uses while launching for nonpatented indications. This can create regulatory entry without immediate full substitution across all approved uses.

How does IMBRUVICA compare with Calquence and Brukinsa?

Factor	IMBRUVICA	Calquence	Brukinsa
Generation	First-generation covalent BTK inhibitor	Second-generation covalent BTK inhibitor	Second-generation covalent BTK inhibitor
Market entry	Earliest broad commercial launch	Later entrant	Later entrant
Main strength	Extensive clinical history and physician familiarity	Safety and selectivity positioning	Efficacy, selectivity, and aggressive commercial expansion
Main weakness	Cardiovascular toxicity and aging patent estate	Competitive pressure and dosing considerations	Limited historical exposure relative to IMBRUVICA
Generic risk	Late-2020s and later	Later than IMBRUVICA	Later than IMBRUVICA
Share outlook	Declining	Growth or stabilization	Growth potential

IMBRUVICA has the largest cumulative installed base but no longer has the same competitive insulation. The product’s remaining value depends on durable use in patients who respond well, physician comfort with its clinical record, and the pace at which newer agents replace it at treatment initiation.

What is IMBRUVICA’s revenue exposure for AbbVie and Johnson & Johnson?

IMBRUVICA is more material to AbbVie’s hematology portfolio than to Johnson & Johnson’s overall pharmaceutical business. For AbbVie, the product remains a multibillion-dollar contributor but is increasingly offset by growth from Skyrizi, Rinvoq, and newer immunology products.

For Johnson & Johnson, IMBRUVICA represents a smaller share of pharmaceutical revenue. The company’s oncology exposure is diversified across Darzalex, Erleada, Carvykti, and other products. As a result, IMBRUVICA’s decline has less impact on Johnson & Johnson’s consolidated financial profile than on AbbVie’s hematology trajectory.

The key financial issue is not an immediate revenue collapse. It is the transition from a high-margin growth product to a mature cash-generating asset that faces branded substitution before broad generic entry.

What licensing deals affect IMBRUVICA?

Pharmacyclics entered into a collaboration with Janssen before AbbVie acquired Pharmacyclics. The arrangement gave Janssen rights to participate in development and commercialization while Pharmacyclics, later controlled by AbbVie, retained the principal economic relationship for its territories.

The collaboration reduced development and commercialization risk and helped create a global sales infrastructure. It also means that reported revenue is divided between the partners, complicating direct comparisons between AbbVie and Johnson & Johnson annual-report figures.

Future licensing activity could involve:

• regional generic rights;
• authorized-generic supply;
• settlements with ANDA filers;
• combination development with other hematology agents;
• post-expiry commercialization arrangements.

What is the outlook for IMBRUVICA through 2030?

IMBRUVICA is likely to follow a declining but still substantial revenue path.

Period	Expected market dynamic
2024-2025	Continued branded erosion from Calquence and Brukinsa; stable use in existing CLL and WM patients
2026-2027	Increased Paragraph IV activity and preparation for generic entry
2028-2029	Greater risk of price erosion and share loss if core patents are not sustained
2030 and later	Potential multi-generic competition, depending on formulation and method patents

The product’s durable value lies in its established patient base, treatment familiarity, and continued use in selected hematologic malignancies. Its principal risk is that new patients increasingly start on newer BTK inhibitors or fixed-duration regimens, reducing the replenishment of the IMBRUVICA population.

Key Takeaways

• IMBRUVICA generated approximately $5.5 billion in combined AbbVie and Johnson & Johnson sales in 2023.
• Revenue peaked before declining under pressure from Calquence, Brukinsa, Jaypirca, and fixed-duration Venclexta-based treatment.
• U.S. mantle cell lymphoma and marginal zone lymphoma indications were withdrawn in 2023.
• The remaining core franchise is concentrated in CLL, SLL, Waldenström macroglobulinemia, and chronic graft-versus-host disease.
• IMBRUVICA has Orange Book-listed patents covering the active ingredient, formulations, and methods of use.
• Generic risk is expected to intensify in the late 2020s, with later patents potentially affecting specific formulations or indications.
• No biosimilar pathway applies because ibrutinib is a small molecule.
• Branded competition is a more immediate threat than generic entry.
• AbbVie has greater financial exposure to IMBRUVICA than Johnson & Johnson.
• The product is transitioning from a growth asset to a mature hematology franchise with declining but material cash flow.

FAQs

Is IMBRUVICA still a blockbuster drug?

Yes. IMBRUVICA remains a multibillion-dollar product, although its sales are declining from peak levels and its market share is under pressure from newer BTK inhibitors.

Does IMBRUVICA have biosimilar competition?

No. Ibrutinib is a chemically synthesized small molecule, so future competitors will enter through the ANDA generic-drug pathway rather than the biosimilar pathway.

Which drug is replacing IMBRUVICA?

Calquence and Brukinsa are the principal direct substitutes in covalent BTK inhibitor treatment. Venclexta-based fixed-duration regimens compete in selected CLL settings, while Jaypirca is used mainly after resistance or intolerance to covalent BTK inhibitors.

Can a generic ibrutinib launch before all IMBRUVICA patents expire?

Yes. A generic could launch through a successful Paragraph IV challenge, a patent settlement, a license, or a court ruling that removes the relevant blocking patent. A skinny-label launch could also target nonpatented uses.

What is the largest long-term risk to IMBRUVICA revenue?

The largest long-term risk is cumulative branded substitution. New patients may begin treatment with Calquence, Brukinsa, or fixed-duration regimens before generic ibrutinib arrives, reducing the population available for IMBRUVICA retention and replacement.

References

1. AbbVie Inc. (2024). 2023 annual report.
2. Johnson & Johnson. (2024). 2023 annual report.
3. AbbVie Inc. (2015). AbbVie completes acquisition of Pharmacyclics.
4. U.S. Food and Drug Administration. (2024). IMBRUVICA (ibrutinib) prescribing information.
5. U.S. Food and Drug Administration. (2023). Withdrawal of approval of indications for IMBRUVICA.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
7. U.S. Code, 21 U.S.C. § 355(j). (2024). Abbreviated applications for new drugs.

DrugChatter Q&A for IMBRUVICA

Patente imbruvica?
Buy imbruvica bulk?
Imbruvica manufacturer?
Imbruvica loss of exclusivity?
Is Imbruvica taken as a pill or injection?